Pharmacokinetics of Ro 03-8799 in mice bearing melanosarcoma: comparison with tumors without melanin
The pharmacokinetics of Ro 03-8799 has been studied in melanic and non-melanic tumor bearing mice after iv administration of 150 mg/kg. The peak concentration in B16 melanosarcoma tumor reached 152 micrograms/g, that is 7.6-fold higher than the plasma concentration at the same time. This concentration is 3-times greater than that obtained in the tumor of mice bearing non-melanic sarcoma (DB16) or Lewis lung carcinoma (3LL). The exposure of B16 tumor (AUC) is respectively 15-times and 11-times higher than the 3LL and the DB16 ones. These experimental data confirm that this 2-nitro-imidazol compound has an important affinity for melanin and suggest that it might be used as a radiosensitizer for the treatment of malignant melanoma.
- Research Organization:
- Faculte des Sciences Pharmaceutiques, Toulouse (France)
- OSTI ID:
- 6252901
- Journal Information:
- Int. J. Radiat. Oncol., Biol. Phys.; (United States), Vol. 16:4
- Country of Publication:
- United States
- Language:
- English
Similar Records
Abnormal clinical pharmacokinetics of the developmental radiosensitizers pimonidazole (Ro 03-8799) and etanidazole (SR 2508)
Multiple dose study of the combined radiosensitizers Ro 03-8799 (pimonidazole) and SR 2508 (etanidazole)
Related Subjects
62 RADIOLOGY AND NUCLEAR MEDICINE
LUNGS
CARCINOMAS
RADIOSENSITIZERS
BIOCHEMICAL REACTION KINETICS
COMPARATIVE EVALUATIONS
EXPERIMENTAL NEOPLASMS
MELANIN
MELANOMAS
MICE
RADIOTHERAPY
SARCOMAS
ANIMALS
BODY
DISEASES
DRUGS
HYDROXY COMPOUNDS
KINETICS
MAMMALS
MEDICINE
NEOPLASMS
NUCLEAR MEDICINE
ORGANIC COMPOUNDS
ORGANIC NITROGEN COMPOUNDS
ORGANS
PIGMENTS
RADIOLOGY
REACTION KINETICS
RESPIRATORY SYSTEM
RODENTS
THERAPY
VERTEBRATES
560152* - Radiation Effects on Animals- Animals
550603 - Medicine- External Radiation in Therapy- (1980-)